Published in J Antibiot (Tokyo) on April 01, 1992
Sequences of beta-lactamase genes encoding CTX-M-1 (MEN-1) and CTX-M-2 and relationship of their amino acid sequences with those of other beta-lactamases. Antimicrob Agents Chemother (1996) 5.36
Experimental evaluation of HR756, a new cephalosporin derivative: pre-clinical study. Infection (1977) 4.89
A new plasmidic cefotaximase from patients infected with Salmonella typhimurium. Infection (1992) 4.52
Characterization of the plasmidic beta-lactamase CMY-2, which is responsible for cephamycin resistance. Antimicrob Agents Chemother (1996) 4.41
Cefotaxime-resistant Enterobacteriaceae isolates from a hospital in Warsaw, Poland: identification of a new CTX-M-3 cefotaxime-hydrolyzing beta-lactamase that is closely related to the CTX-M-1/MEN-1 enzyme. Antimicrob Agents Chemother (1998) 4.24
Characterization of beta-lactamase gene blaPER-2, which encodes an extended-spectrum class A beta-lactamase. Antimicrob Agents Chemother (1996) 3.56
A community study of diabetes in Oxfordshire. J R Coll Gen Pract (1983) 2.88
Comparative characterization of the cephamycinase blaCMY-1 gene and its relationship with other beta-lactamase genes. Antimicrob Agents Chemother (1996) 2.77
Continuous cell lines and immune ascitic fluid pools in arbovirus detection. Res Virol (1993) 2.64
Comparison of the antibacterial in vitro and in vivo activity of ofloxacin (HOE 280 DL 8280) and nalidixic acid analogues. Eur J Clin Microbiol (1983) 2.45
A novel type of AmpC beta-lactamase, ACC-1, produced by a Klebsiella pneumoniae strain causing nosocomial pneumonia. Antimicrob Agents Chemother (1999) 2.40
[Surveillance of the circulation of arbovirus of medical interest in the region of eastern Senegal]. Bull Soc Pathol Exot (1993) 2.35
Pushing the limits of in vivo diffusion MRI for the Human Connectome Project. Neuroimage (2013) 2.31
The children's hour: the State Children's Health Insurance Program. Health Aff (Millwood) (1998) 1.95
Ability of the T cell-replacing polyanion dextran sulfate to trigger the alternate pathway of complement activation. Eur J Immunol (1973) 1.68
A novel class C beta-lactamase (FOX-2) in Escherichia coli conferring resistance to cephamycins. Antimicrob Agents Chemother (1997) 1.64
Discrimination of Burkholderia gladioli from other Burkholderia species detectable in cystic fibrosis patients by PCR. J Clin Microbiol (1998) 1.60
Ceftazidime-resistant Enterobacteriaceae isolates from three Polish hospitals: identification of three novel TEM- and SHV-5-type extended-spectrum beta-lactamases. Antimicrob Agents Chemother (1998) 1.58
Spread of Klebsiella pneumoniae producing SHV-5 beta-lactamase among hospitalized patients. Infection (1993) 1.52
Mode of action of the lantibiotic mersacidin: inhibition of peptidoglycan biosynthesis via a novel mechanism? Antimicrob Agents Chemother (1995) 1.52
[The antibacterial activity in vitro of ofloxacin in comparison with other orally administered antimicrobial substances on ampicillin-resistant clinical isolates]. Arzneimittelforschung (1984) 1.50
Comparative pharmacodynamics of clarithromycin and azithromycin against respiratory pathogens. Infection (1996) 1.50
Isolations of West Nile and Bagaza viruses from mosquitoes (Diptera: Culicidae) in central Senegal (Ferlo). J Med Entomol (1994) 1.49
Oxidation and dehalogenation of 4-chlorophenylacetate by a two-component enzyme system from Pseudomonas sp. strain CBS3. J Bacteriol (1984) 1.47
Purification and some properties of component A of the 4-chlorophenylacetate 3,4-dioxygenase from Pseudomonas species strain CBS. J Biol Chem (1986) 1.46
Mersacidin, a new antibiotic from Bacillus. In vitro and in vivo antibacterial activity. J Antibiot (Tokyo) (1992) 1.44
DNP-antigens activate the alternate pathway of the complement system. J Immunol (1974) 1.44
Qualitative and quantitative microbiological analysis of sputa of 102 patients with cystic fibrosis. Infection (1987) 1.43
Discrimination of Burkholderia multivorans and Burkholderia vietnamiensis from Burkholderia cepacia genomovars I, III, and IV by PCR. J Clin Microbiol (1999) 1.43
Molecular procedure for rapid detection of Burkholderia mallei and Burkholderia pseudomallei. J Clin Microbiol (1998) 1.42
The Antibacterial activity in vitro and beta-lactamase stability of the new cephalosporin HR 810 in comparison with five other cephalosporins and two aminoglycosides. Infection (1984) 1.41
Activation by some T-independent antigens and B cell mitogens of the alternative pathway of the complement system. J Immunol (1975) 1.39
Degradation of 4-chlorophenylacetic acid by a Pseudomonas species. J Bacteriol (1981) 1.32
Pharmacokinetic properties of the new cephalosporin antibiotic HR 810 in animals. Infection (1984) 1.28
Arbovirus surveillance from 1990 to 1995 in the Barkedji area (Ferlo) of Senegal, a possible natural focus of Rift Valley fever virus. J Med Entomol (2001) 1.27
HR 810, a new parenteral cephalosporin with a broad antibacterial spectrum. Arzneimittelforschung (1983) 1.27
An RVF epidemic in southern Mauritania. Ann Inst Pasteur Virol (1989) 1.26
Cefodizime, an aminothiazolyl cephalosporin. IV. Influence on the immune system. J Antibiot (Tokyo) (1984) 1.25
[Microbial degradation and 4-chlorophenylacetic acid. Chemical synthesis of 3-chloro-4-hydroxy-, 4-chloro-3-hydroxy- and 4-chloro-2-hydroxyphenylacetic acid (author's transl)]. Hoppe Seylers Z Physiol Chem (1982) 1.21
Lymphocytes in the bronchoalveolar space reenter the lung tissue by means of the alveolar epithelium, migrate to regional lymph nodes, and subsequently rejoin the systemic immune system. Anat Rec (2001) 1.18
Dengue 2 outbreak in southeastern Senegal during 1990: virus isolations from mosquitoes (Diptera: Culicidae). J Med Entomol (1994) 1.13
Lues maligna, or ulceronodular syphilis, in a man infected with human immunodeficiency virus: case report and review. Clin Infect Dis (1995) 1.11
Factor D in the alternate pathway of complement activation: purification, physicochemical characterization and functional role. Immunochemistry (1974) 1.09
Formation of transmural complement pores in serum-sensitive Escherichia coli. Infect Immun (1987) 1.08
The in-vitro antibacterial activity of a combination of cefpirome or cefoperazone with vancomycin against enterococci and Staphylococcus aureus. J Antimicrob Chemother (1992) 1.07
[Crimean-Congo hemorrhagic fever in Senegal. Latest data on the ecology of the CCHF virus]. Bull Soc Pathol Exot (1994) 1.05
Balhimycin, a new glycopeptide antibiotic produced by Amycolatopsis sp. Y-86,21022. Taxonomy, production, isolation and biological activity. J Antibiot (Tokyo) (1994) 1.05
Purification and some properties of component B of the 4-chlorophenylacetate 3,4-dioxygenase from Pseudomonas species strain CBS 3. J Biol Chem (1987) 1.04
Simultaneous simulation of the serum profiles of two antibiotics and analysis of the combined effect against a culture of Pseudomonas aeruginosa. Chemotherapy (1982) 1.03
The conservation of poly-A-containing RNA during the dormant state of the moss Polytrichum commune. Nucleic Acids Res (1976) 1.01
Friulimicins: novel lipopeptide antibiotics with peptidoglycan synthesis inhibiting activity from Actinoplanes friuliensis sp. nov. II. Isolation and structural characterization. J Antibiot (Tokyo) (2000) 1.01
Antibacterial activities in vitro and in vivo and pharmacokinetics of cefquinome (HR 111V), a new broad-spectrum cephalosporin. Antimicrob Agents Chemother (1991) 1.00
Cefodizime, an aminothiazolylcephalosporin. II. Comparative studies on the pharmacokinetic behavior in laboratory animals. J Antibiot (Tokyo) (1984) 1.00
Dose linearity testing of intravenous cefpirome (HR 810), a novel cephalosporin derivate. Infection (1987) 1.00
Effect of cordycepin on nucleic acid metabolism in L5178Y cells and on nucleic acid-synthesizing enzyme systems. Cancer Res (1977) 1.00
Analytical study of a Rift Valley fever epidemic. Res Virol (1989) 1.00
Chemotherapeutic activity of levofloxacin (HR 355, DR-3355) against systemic and localized infections in laboratory animals. J Antimicrob Chemother (1995) 0.99
Potent antileukemic activity of the novel cytostatic agent avarone and its analogues in vitro and in vivo. Cancer Res (1985) 0.99
Cefodizime in serum and skin blister fluid after single intravenous and intramuscular doses in healthy volunteers. Antimicrob Agents Chemother (1987) 0.99
World pandemic of obesity: the situation in Southern African populations. Public Health (2001) 0.98
Surveillance for yellow fever virus in eastern Senegal during 1993. J Med Entomol (1996) 0.97
Multiclonal emergence of ciprofloxacin-resistant clinical isolates of Escherichia coli and Klebsiella pneumoniae. J Antimicrob Chemother (1994) 0.97
Single and multiple dose pharmacokinetics of intravenous cefpirome (HR 810), a novel cephalosporin derivative. Infection (1987) 0.96
Endoscopic photodynamic therapy with hematoporphyrin derivative for primary treatment of gastrointestinal neoplasms in inoperable patients. Dig Dis Sci (1990) 0.95
Cefodizime penetration into skin suction blister fluid following a single intravenous dose. Eur J Clin Pharmacol (1986) 0.95
Purification and characterization of a cephalosporinase from E. coli. Zentralbl Bakteriol Mikrobiol Hyg A (1982) 0.95
Chemotherapeutic effects of ofloxacin (HOE 280) and other quinolone-carboxylic derivates in the treatment of experimental lung infections due to Klebsiella pneumoniae DT-S in mice. Infection (1986) 0.95
[An enzymic method for the determination of cefotaxim in serum and urine (author's transl)]. J Clin Chem Clin Biochem (1981) 0.94